



ADVITECH'S XP-828L PROCESS GRANTED U.S. PATENT

TSX VENTURE EXCHANGE: AVI

FOR IMMEDIATE RELEASE

QUÉBEC – DECEMBER 22, 2006 – Advitech inc. (“Advitech”) (TSX Venture: AVI) today announced that the U.S. Patent and Trademark Office has issued the patent protecting the manufacturing process of its technological platform XP-828L (US 7,141,262 B2) on the U.S. market.

The process developed by Advitech from the previous work of Pierre Jouan Biotechnologies (France) is covered by this patent, which protects the manufacturing process for Dermylex™, a natural oral health product that relieves mild-to-moderate psoriasis symptoms. This new patent, combined with the previous ones obtained for Europe and New Zealand, strengthens Advitech's position as to the protection of its intellectual property.

“This news confirms the value of Advitech's intellectual property portfolio and of its XP-828L technological platform for chronic inflammatory disorders such as psoriasis,” stated Christina Juneau PhD, Vice-President for Research and Development at Advitech.

About Advitech Inc.

Advitech is a health sciences and technology company with a mission to discover and commercialize proprietary and evidence-based natural health products. Effective and safe, these products play a role in the prevention of Immune-Mediated Inflammatory Disorders (IMID), such as psoriasis and inflammatory bowel disease. Advitech's common shares are listed on the TSX Venture Exchange under the symbol AVI. The number of common shares outstanding is 61,247,318. The NEW Dermylex™ website is now online at www.dermylex.ca.

About Dermylex™

Dermylex™, developed by Advitech, is an oral natural health product relieving mild-to-moderate psoriasis symptoms. Two clinical trials, one of them multi-center, double-blind and placebo-controlled, for 112 days and on 84 patients, clinically proved the efficacy and safety of Dermylex™ for that type of psoriasis. Dermylex™ is currently available in Canada. For more information, please visit the www.dermylex.ca website.

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Advitech Inc.

Renaud Beauchesne, MBA
President and Chief Executive Officer
(418) 686-7498, ext. 228
info@advitech.com
www.advitech.com
www.dermylex.ca